Systemic Vasculitis

05/01/1996 - "Regardless of whether they are pathogenic, sequential measurement of anti-neutrophil cytoplasmic antibody titres have proved extremely useful in the management of patients with systemic vasculitis. "
07/01/1991 - "It is concluded that ANCA are very helpful in the diagnosis of systemic vasculitis, notably in cases with first-time alveolar haemorrhage. "
11/01/2006 - "Maintenance of remission is a more difficult target, and evidence from studies of patients with antineutrophil cytoplasmic antibody (ANCA)-associated systemic vasculitis indicates that durable, lasting remission is unlikely to occur. "
12/01/2008 - "Monocytes have been shown to be activated in ANCA-positive systemic vasculitis, but their state of activation in clinical remission is unknown.Fifteen"
11/01/2006 - "Remission in antineutrophil cytoplasmic antibody-associated systemic vasculitis."

10/01/1994 - "The efficacy of cyclophosphamide (CY) in the treatment of severe systemic vasculitis has been demonstrated, but its optimal administration regimen remains to be defined. "
10/01/1990 - "Concerns regarding the long-term toxicity of daily cyclophosphamide (CP) therapy for the systemic vasculitides have led us to evaluate alternative approaches to treatment in an attempt to achieve comparable efficacy with less toxicity. "
01/01/1986 - "Combined cyclophosphamide and corticosteroid-induced remission in severe glomerulopathy associated with systemic vasculitis."
01/01/2010 - "Therefore, the major challenge in the treatment of systemic vasculitis is the search for treatments that are less toxic, but similarly effective compared to cyclophosphamide. "
01/01/2009 - "Due to the well known toxicities of cyclophosphamide, substantial interest exists in finding other therapies to treat primary systemic vasculitis. "

01/01/2011 - "In this sample of patients with systemic vasculitis who were refractory or intolerant to more conventional treatment, rituximab proved to be safe and effective in a long-term follow-up, and showed steroid- and immunosuppressive-sparing effects allowing the persistence of long-lasting remissions without maintenance therapy."
02/01/2008 - "Based on this experience and a number of reports published in the last 5 years, Rituximab appears to be a safe and effective therapeutic option in symptomatic patients with HCV-associated MC with signs of systemic vasculitis."
05/01/2008 - "In this sample of patients with idiopathic systemic vasculitis that was refractory or intolerant to conventional treatment, rituximab was found to be a safe and effective rescue therapy."
09/01/2011 - "Long-term follow-up of different refractory systemic vasculitides treated with rituximab."
12/01/2010 - "Rituximab for rescue and maintenance therapy in rapidly progressive life-threatening antineutrophil cytoplasmic autoantibody-associated systemic vasculitis."

01/01/1993 - "In the patients with systemic vasculitis and SLE, there was successful removal of autoantibodies and rapid control of disease; remission was maintained over a mean follow-up of 2 years. "
01/01/2016 - "Usefulness of antineutrophil cytoplasmic autoantibodies in diagnosing and managing systemic vasculitis."
01/01/2015 - "Autoantibodies in systemic vasculitis."
02/01/2013 - "Anti-neutrophil cytoplasmic autoantibodies: methodological aspects and clinical significance in systemic vasculitis."
09/01/2010 - "Taken together, our data suggest that anti-Prx2 autoantibodies would be a useful marker for systemic vasculitis and would be involved in the inflammatory processes of systemic vasculitis."

01/01/1993 - "The efficacy and safety of IVIg (Sandoglobulin) was assessed in an open study of 26 patients with active systemic vasculitis. "
05/01/1996 - "New treatment strategies for systemic vasculitis: the role of intravenous immune globulin therapy."
02/01/1991 - "IVIg may modulate the activity of systemic vasculitis in vivo."
12/01/2011 - "Kawasaki disease (KD) is an acute systemic vasculitis associated with the development of coronary arterial lesions (CALs) occurring in 3-5% of children treated by intravenous immune globulin (IVIG). "
07/01/1994 - "Treatment of autoimmune diseases and systemic vasculitis with pooled human intravenous immune globulin."

07/01/2006 - "Infliximab leads to a rapid but transient improvement in endothelial function in patients with primary systemic vasculitis."
04/01/2007 - "Infliximab in patients with systemic vasculitis that is difficult to treat: poor outcome and significant adverse effects."
09/01/2006 - "We describe a 10-year-old girl with systemic vasculitis resistant to immunosuppressive treatment who had a rapid and impressive response to treatment with infliximab."
09/01/2006 - "Infliximab in a child with therapy-resistant systemic vasculitis."
10/01/2010 - "Uncontrolled studies have pointed to the efficacy of TNFα blockade with infliximab in the induction of remission in systemic vasculitides. "

11/01/2008 - "The patient was initially treated with corticosteroids, but 10 months after the discovery and surgical repair of the AVM, the patient is not receiving any immunosuppressant and has not developed any features of cerebral or systemic vasculitis."
09/01/2006 - "Treatment of systemic vasculitides is usually based on the use of corticosteroids and other immunosuppressive drugs. "
02/01/2000 - "Systemic vasculitis, which had been a consistently fatal disorder, became curable, with a sometimes chronic progression, when treatment with corticosteroids in association with immunosuppressive drugs was introduced. "
10/01/1999 - "Initial therapy for most types of systemic vasculitis consists of high-dose corticosteroids, with the addition of immunosuppressive therapy in certain patients."
01/01/1998 - "The prognosis of systemic vasculitides has been transformed by corticosteroids that are, except in HBV-related PAN, the basic treatment. "

01/01/2014 - "GCA, an antigen-driven systemic vasculitis affecting medium and large blood vessels of elderly people, represents one of these cases. "
12/07/2005 - "[Prevalence of antiepithelial cell antibody in systemic vasculitis and identification of the target antigen thereof]."
01/01/1998 - "Models of antineutrophil cytoplasmic antigen-associated systemic vasculitis and their clinical relevance."
05/01/1995 - "Endothelial cells demonstrably recruit leukocytes by both antigen-specific and antigen-nonspecific mechanisms in the systemic vasculitides. "
08/01/1993 - "In order to select B cells recognizing endothelial cells antigens, Epstein-Barr virus (EBV)-infected B cells, obtained from one patient presenting a systemic vasculitis, were cocultured with human endothelial cells concurrently with a human endothelial cell line (EC-pSV1 cells). "

04/01/2007 - "Until now, a few controlled studies investigated the efficacy of TNF-alpha blocking agents in systemic vasculitis have been carried out, but, in general, they were falling short of expectations. "
01/01/2014 - "Anti-TNF-alpha therapy and systemic vasculitis."
07/26/2013 - "Tumor necrosis factor (TNF)-α is the pleiotropic inflammatory cytokine elevated during the acute phase of KD, which induces damage to vascular endothelial cells to cause systemic vasculitis. "
03/01/2013 - "Since their routine use, however, tumor necrosis factor inhibitors have been associated with the development of drug-induced complications including the induction of lupus and both cutaneous and systemic vasculitis. "
04/01/2006 - "In this review, we examine the up-to-date evidence for the use of biologics in systemic vasculitis, including TNF-alpha inhibitors, and highlight the challenges facing their use. "

01/01/2011 - "Furthermore, we discuss the possible significance of AECA in the pathophysiology of vascular damage and the value of AECA in systemic vasculitis. "
12/01/2005 - "But AECA could also be found in other systemic vasculitis and SLE."
10/02/2004 - "Prevalence of AECA in systemic vasculitis is high. "
10/02/2004 - "With either EA.hy926 or HMEC-1 as substrates, the AECA prevalence rates of systemic vasculitis (respectively 33.61% and 37.70%) were significantly higher than those of the normal and RA groups (less than 10%), and the prevalence of AECA in SLE (61.75%) was higher than that of systemic vasculitis (37.70%) when using HMEC-1 as substrates. "
09/01/2004 - "Heterogeneity of endothelial cells necessitates use of clinically relevant endothelial cells for elucidation of the role of AECA in systemic vasculitis involving small blood vessels of specific organs. "

06/01/2014 - "GPA is a systemic vasculitis with a high relapse rate despite successful remission induction. "
07/01/2008 - "For patients with systemic vasculitis (SV) refractory to conventional therapy, new treatment strategies aimed at aggressive induction of remission and relapse prevention are being sought. "
10/01/2010 - "Uncontrolled studies have pointed to the efficacy of TNFα blockade with infliximab in the induction of remission in systemic vasculitides. "
09/01/2011 - "There is increasing interest in rituximab (RTX) as an alternative to cyclophosphamide (CYC) for remission induction in systemic vasculitis. "
12/01/2003 - "In primary systemic vasculitides of small- or medium-sized vessels induction of remission therapy comprises methotrexate in early generalized disease without significant renal insufficiency, cyclophosphamide in full-blown generalized disease and additional plasma exchanges in cases of rapidly progressive glomerulonephritis if oliguric, each in conjunction with oral prednisolone. "

10/01/2009 - "We then identified 107 renal allograft recipients whose primary disease was systemic vasculitis and assessed their outcome post-transplant. "
01/01/1993 - "Late recurrence of systemic vasculitis after kidney transplantation involving the kidney allograft."
02/01/2012 - "Indications for the use of a homograft were systemic vasculitis (n=15) and complicated infection (n=8). "
07/01/1994 - "A 59-year-old man with end-stage renal failure from systemic vasculitis developed de novo immunotactoid glomerulopathy of the renal allograft, with clinical evidence of hematuria, proteinuria, and acute renal failure 6 weeks after cadaveric renal transplantation. "
05/01/1995 - "This study measured the serum concentrations of circulating adhesion molecules (cICAM-1, cVCAM-1, cE-Selectin) by sandwich ELISA in systemic vasculitis with renal involvement (Wegener's granulomatosis WG, n = 25; systemic lupus erythematosus SLE, n = 50) in comparison to chronic glomerulonephritis (n = 10), stable renal allograft function and end-stage renal disease (CAPD/hemodialysis, each n = 10). "

12/01/1994 - "Approaches to specific immunotherapy for systemic vasculitis."
01/01/1994 - "Increased understanding of the pathogenesis of systemic vasculitis is likely to provide the basis for the use of more specific immunotherapies in the future."
11/23/1992 - "Immunotherapy with IVIG in diseases of autoimmune character such as acute and chronic demyelinating neuropathy has recently shown promising results and encouraging reports have been published in the treatment of severe, steroid-dependent asthma, juvenile chronic arthritis and systemic vasculitis and dermatomyositis where IVIG possibly has a favourable immunomodulating effect on the patient's immune response. "

11/01/2008 - "Numerous case reports featuring its off-label use suggest the drug could be helpful in treating hidradenitis suppurativa, pyoderma gangrenosum, Sweet's syndrome, cutaneous sarcoidosis, pemphigus, systemic vasculitides, multicentric reticulohistiocytosis and stomatitis."

05/01/2004 - "Critical care physicians must recognize neurologic manifestation patterns of systemic vasculitides because appropriate diagnosis and therapy result in significantly improved morbidity and mortality."